文献速递神经肌肉病

电阻抗肌电图检测面肩肱型肌营养不良症12至24个月疾病进展

Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy.
PubMed 文献 · Ann Neurol · 2026-02-22

结果显示EIM相位参数重测信度优秀,与FSHD复合结局指标强相关,且在12至24个月期间可检测到显著下降,提示其作为FSHD临床试验生物标志物的潜力。

要点

  • EIM相位参数在FSHD患者中重测信度优秀(ICC≥0.94)。
  • EIM相位与FSHD-COM和MFM1强相关,电抗相关性中等。
  • EIM相位在12至24个月期间显著下降,电抗变化不显著。

核心结论

  • EIM相位参数可靠、有效且对12至24个月内的病情变化敏感,支持其作为FSHD临床试验生物标志物的潜在用途。

研究设计与样本

  • 对6块肌肉(三角肌、肱二头肌、肱三头肌、股外侧肌、胫骨前肌、腓肠肌内侧头)双侧进行EIM检测。

主要发现

  • 所有EIM结局的重测信度优秀(ICC≥0.94)。
  • 相位参数与FSHD-COM强相关(r≤-0.69),与MFM1强相关(r≥0.75);电抗与FSHD-COM中等相关(r≥-0.41),与MFM1中等相关(r≤0.44)。
  • 12个月时相位和相位比出现平均下降,例如50 kHz下为-0.25(95%CI -0.45至-0.05),并持续至24个月:50 kHz下为-0.66(95%CI -0.92至-0.40),100 kHz下为-0.65(95%CI -0.87至-0.44),均p<0.0001。
  • 电抗变化较小且不显著:50 kHz下为-0.21(95%CI -0.44至0.02),100 kHz下为-0.13(95%CI -0.35至0.10)。

关键数值与推荐

  • EIM相位参数重测信度ICC≥0.94。
  • 相位与FSHD-COM的相关系数r≤-0.69,与MFM1的相关系数r≥0.75。
  • 24个月时50 kHz相位下降-0.66(95%CI -0.92至-0.40),100 kHz相位下降-0.65(95%CI -0.87至-0.44),均p<0.0001。

临床怎么用

  • EIM相位参数可作为FSHD临床试验中监测疾病进展的非侵入性生物标志物,尤其适用于早期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Targeted therapies for facioscapulohumeral muscular dystrophy (FSHD) are progressing through clinical trials. Electrical impedance myography (EIM) provides a noninvasive biomarker of muscle composition that may be valuable especially in early phase trials. This study evaluated EIM data from a multicenter FSHD cohort over 24 months. METHODS: Adult patients with FSHD at 8 sites underwent EIM in 6 muscles bilaterally (deltoid, biceps, triceps, vastus lateralis, tibialis anterior, and medial gastrocnemius). EIM outcomes phase and reactance (50 and 100 kHz [kilohertz] frequencies) and 50 of 211 kHz phase ratio were evaluated for reliability, correlations with clinical measures, and sensitivity to change. RESULTS: One hundred fifty-seven patients (53% male patients) were included. Test-retest reliability was excellent for all EIM outcomes (intraclass correlation coefficient [ICC] ≥0.94). Phase outcomes strongly correlated with the FSHD-composite outcome measure (FSHD-COM; r ≤ -0.69) and Motor Function Measure Domain 1 (MFM1; r ≥ 0.75); reactance outcomes exhibited moderate correlations with the FSHD-COM (r ≥ -0.41) and MFM1 (r ≤ 0.44). Mean declines in phase and phase ratio were apparent at 12 months (eg, -0.25, 95% confidence interval [CI] = -0.45 to -0.05 at 50 kHz), and further progressed through 24 months (-0.66, 95% CI = -0.92 to -0.40] at 50 kHz and -0.65 [95% CI = -0.87 to -0.44] at 100 kHz; both p < 0.0001). Reactance changes were smaller and not significant: -0.21 (95% CI = -0.44 to 0.02) at 50 kHz and -0.13 (95% CI = -0.35 to 0.10) at 100 kHz. INTERPRETATION: EIM phase outcomes are reliable, valid, and sensitive to change over 12 to 24 months, supporting their potential utility as biomarkers in FSHD clinical trials. ANN NEUROL 2026;99:1545-1554.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Mul K, McDermott MP, Butterfield RJ, et al. Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy. Ann Neurol. 2026. PMID: 41724900. doi:10.1002/ana.78182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。